Aratana Therapeutics Inc (NASDAQ:PETX)’s share price dropped 14.2% during trading on Wednesday . The company traded as low as $3.78 and last traded at $3.80. Approximately 1,460,570 shares were traded during trading, an increase of 247% from the average daily volume of 420,959 shares. The stock had previously closed at $4.43.

PETX has been the topic of a number of recent research reports. Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 18th. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 21st. ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. CL King upgraded Aratana Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Monday. They noted that the move was a valuation call. Finally, Stifel Nicolaus restated a “hold” rating and set a $6.00 price objective on shares of Aratana Therapeutics in a research note on Monday, December 18th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Aratana Therapeutics presently has an average rating of “Hold” and a consensus target price of $8.46.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08. The firm has a market capitalization of $163.39, a P/E ratio of -2.62 and a beta of 3.13.

In other news, insider Craig A. Tooman sold 30,000 shares of Aratana Therapeutics stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $5.27, for a total value of $158,100.00. Following the transaction, the insider now owns 75,024 shares in the company, valued at approximately $395,376.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Peter Steven St sold 19,367 shares of Aratana Therapeutics stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total value of $92,380.59. Following the completion of the transaction, the chief executive officer now owns 672,259 shares in the company, valued at approximately $3,206,675.43. The disclosure for this sale can be found here. Company insiders own 5.20% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of PETX. Northern Trust Corp increased its stake in shares of Aratana Therapeutics by 10.5% in the 2nd quarter. Northern Trust Corp now owns 463,984 shares of the biopharmaceutical company’s stock valued at $3,355,000 after purchasing an additional 43,967 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in shares of Aratana Therapeutics by 6.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 1,875 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Aratana Therapeutics by 197.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 380,895 shares of the biopharmaceutical company’s stock valued at $2,754,000 after purchasing an additional 252,655 shares during the last quarter. Voya Investment Management LLC increased its stake in shares of Aratana Therapeutics by 22.7% in the 2nd quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 3,610 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Aratana Therapeutics by 10.2% in the 2nd quarter. State Street Corp now owns 597,180 shares of the biopharmaceutical company’s stock valued at $4,317,000 after purchasing an additional 55,480 shares during the last quarter. Institutional investors own 71.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Aratana Therapeutics (PETX) Trading Down 14.2%” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2018/03/14/aratana-therapeutics-petx-trading-down-14-2.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.